IDH Inhibitors in Acute Myeloid Leukemia and Myelodysplastic Syndrome

H&O How common are isocitrate dehydrogenase (IDH) mutations in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)? ES At diagnosis, approximately 20% to 25% […]

Recent Advances in the Cellular and Molecular Understanding of Myelodysplastic Syndromes: Implications for New Therapeutic Approaches

Abstract: It has been more than 10 years since any new disease-modifying therapies have received regulatory approval for indications related to myelodysplastic syndromes (MDS). Advances […]